Diagnosis and management of high-risk and metastatic melanoma

Seminars in Oncology Nursing

Volumn 19, Issue 1, 2003, Pages 32-42

  Hollis, Genevieve ^a   Recio, Adriana ^b   Schuchter, Lynn ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CANCER VACCINE; CISPLATIN; DACARBAZINE; DEXAMETHASONE; GRANISETRON; IMMUNOSUPPRESSIVE AGENT; ONDANSETRON; TAMOXIFEN; TEMOZOLOMIDE; ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ALOPECIA; ANOREXIA; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CHILL; CLINICAL EXAMINATION; CLINICAL TRIAL; DEPRESSION; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; LYMPH NODE DISSECTION; MEDICAL LITERATURE; MEDICAL RESEARCH; MELANOMA; METASTASIS; MYALGIA; NAUSEA; NURSING; PAIN; PATIENT CARE; PATIENT EDUCATION; PROGNOSIS; REVIEW; SIDE EFFECT; SKIN DISEASE; TASTE DISORDER; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AFTERCARE; CANCER STAGING; DRUG MONITORING; GENE THERAPY; LYMPHADENECTOMY; METHODOLOGY; NURSE ATTITUDE; RISK ASSESSMENT; RISK FACTOR; SKIN TUMOR;

ADJUVANTS, IMMUNOLOGIC; AFTERCARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DRUG MONITORING; GENE THERAPY; HUMANS; INTERFERON ALFA-2A; LYMPH NODE EXCISION; MELANOMA; NEOPLASM STAGING; NURSE'S ROLE; PATIENT EDUCATION; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS;

EID: 0037313453     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonu.2003.50002     Document Type: Article

References (46)

1. Balch CM, Buzaid AC, and Soong SJ Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 2001 3635 3648
2. Lamb LA, Halpern AC, and Hwu WJ Diagnosis and management of stage I/II melanoma Semin Oncol Nurs 19 2003 22 31
3. Buzaid A, Sandler A, and Mani S Role of computed tomography in the staging of primary melanoma J Clin Oncol 11 1993 638 643
4. Balch CM, Soong SJ, and Bartolucci AA Efficacy of an elective lymph node dissection of 1-4 mm thick melanoma for patients 60 years of age or younger Ann Surg 224 1996 255 263
5. Ross M, Reintgen D, and Balch C Selective lymphadenectomy: Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma Semin Surg Oncol 9 1993 219 223
6. Mansfield PF, Ames FC, and Balch CM Axillary lymph node dissection Balch CM Houghton AN Sober AJ Soong S-J Cutaneous Melanoma (ed 3) 1998 Quality Medical Publishing St Louis 259 268
7. Rapaport DP, Stadelmann WK, and Reintgen DS Inguinal lymphadenectomy Balch CM Houghton ANB Sober AJ Soong S-J Cutaneous Melanoma (ed 3) 1998 Quality Medical Publishing St Louis 269 280
8. O'Brien P Lymphedema Prin Pract Support Oncol Update 2 1999 1 11
9. Kirkwood JM, Strawderman MH, and Ernstoff MS Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17
10. Kirkwood JM, Ibrahim J, and Sondak V High and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2000 2444 2458
11. Kirkwood JM, Ibrahim JG, and Sosman JA High dose Interferon alfa-2b significantly prolongs relapse free and overall survival compared with the GM2-KLH/QS21 vaccine in patients with resected stage IIB/III melanoma: Results of Intergroup Trial E1694/S9512/C509801 J Clin Oncol 19 2002 2370 2380
12. Mussleman DL, Lawson DH, and Gumnick JF Paroxetine for the prevention of depression induced by high-dose interferon alfa N Engl J Med 344 2001 961 966
13. Stafford-Fox V, and Guindon KM Cutaneous reactions associated with alpha interferon therapy Clin J Oncol Nurs 4 2000 164 168
14. Eggermont A European approach to the treatment of malignant melanoma Curr Opin Oncol 14 2002 205 211
15. Morton DL, and Barth A Vaccine therapy for malignant melanoma CA Cancer J Clin 46 1996 225 244
16. Sosman JA, Unger JM, and Liu PY Adjuvant immunotherapy of resected, intermediate-thickness node-negative melanoma with an allogeneic vaccine: Impact of HLA class I antigen expression on outcome J Clin Oncol 20 2002 2067 2075
17. Berd D, Maguire HC, and Schuchter LM Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases J Clin Oncol 15 1997 2359 2370
18. Haigh PI, Difronzo LA, and Gammon G Vaccine therapy for patients with melanoma Oncol 13 1999 1561 1574
19. Germain RN MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation Cell 76 1994 287 299
20. Kubo RT, Sette A, and Grey HM Definition of specific peptide motifs for four major HLA-A alleles J Immunol 152 1994 3913 3924
21. Mitchell MS, Harel W, and Groshen S Association of HLA phenotype with response to active specific immunotherapy of melanoma J Clin Oncol 10 1992 1158 1164
22. Sondak VK, Liu PY, and Tuthill RJ Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group J Clin Oncol 20 2002 2058 2066
23. Stevens G, Thompson JF, and Firth I Locally advanced melanoma: Results of postoperative hypofractionated radiation therapy Cancer 88 2000 88 94
24. Ang KK, Geara FB, and Byers RM Radiotherapy for melanoma Balch CM Houghton AN Sober AJ Soong S-J Cutaneous Melanoma (ed 3) 1998 Quality Medical Publishing St Louis 389 401
25. Langley R, Barnhill R, and Mihm MC Neoplasm: Cutaneous melanoma Freeberg IM Eisen AZ Wolfe K Fitzpatrick's Dermatology in General Medicine (ed 5) 1999 McGraw Hill New York 1080 1116
26. Maguire-Eisen M Risk assessment and early detection of skin cancers Semin Oncol Nurs 19 2003 43 51
27. Mahon S Skin cancer prevention: Education and public health issues Semin Oncol Nurs 19 2003 52 61
28. Myers ML, and Balch CM Diagnosis and treatment of metastatic melanoma Balch CM Houghton AN Sober AJ Soong S-J Cutaneous Melanoma (ed 3) 1998 Quality Medical Publishing St Louis, MO 325 372
29. Barth A, Wanek LA, and Morton DL Prognostic factors in 1,521 melanoma patients with distant metastases J Am Coll Surg 181 1995 193 201
30. Balch CM, Soong J-J, and Murad TM A multifactorial analysis of melanoma: IV. Prognostic factors in 2000 melanoma patients with distant metastases (stage III) J Clin Oncol 1 1983 126 134
31. Atkins MB The treatment of metastatic melanoma with chemotherapy and biologics Curr Opin Oncol 9 1997 205 213
32. Bleehen NM, Newlands SM, and Thatcher LN Cancer research campaign phase II trial of temozolomide in metastatic melanoma J Clin Oncol 13 1995 910 913
33. (abstr) Hwu W, Panogeas ICS, and Known SE Phase I study of temozolomide and thalidomide in the treatment of melanoma Proc Am Soc Clin Oncol 20 2002 3579
34. McClay EF, Mastrangelo MJ, and Berd D Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials Int J Cancer 50 1992 553 556
35. Chapman PB, Einhorn LH, and Meyers ML Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma J Clin Oncol 17 1999 2745 2751
36. Legha SS, Ring S, and Papadopoulous N A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma Cancer 64 1989 2024 2029
37. Argawala SS, and Kirkwood JM Interferons in melanoma Curr Opin Oncol 8 1996 167 174
38. Atkins MB, Kurkel L, and Rosenberg SA High dose recombinant interleukin-2 therapy of patients with metastatic melanoma: Long-term survival update Cancer J Sci Am 6 suppl 1 2000 S11 S14
39. Atkins MB, Lotze M, and Dutcher JP High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated from 1985-1993 J Clin Oncol 17 1999 2105 2116
40. Atkins MB, O'Boyle KR, and Sosman JA Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma J Clin Oncol 12 1994 1553 1560
41. Rosenberg SA, Yang JC, and Schwartzentruber DJ Prospective randomized clinical trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b J Clin Oncol 17 1999 968 975
42. Martin M Management of biochemotherapy-induced toxicity Biother Consid Oncol Nurs 5 2001 6 15
43. Gutzmer R, and Guerry D Gene therapy for melanoma in humans Hematol Oncol Clin North Am 12 1998 519 539
44. Sotomayor MG, Yu H, and Antonia S Advances in gene therapy for malignant melanoma Cancer Control 9 2002 39 48
45. Karakousis CP, Velez A, and Driscoll DL Metastectomy in malignant melanoma Surgery 115 1994 295 302
46. Fraker DL Hyperthermic regional perfusion for melanoma of the limbs Balch CM Houghton AN Sober AJ Soong S-J Cutaneous Melanoma (ed 3) 1998 Quality Medical Publishing St Louis 281 300